{"gene":"CCR1","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1997,"finding":"CCR1 (beta-chemokine receptor) binds MIP-1alpha and RANTES, and its genetic deletion protects mice from pulmonary inflammation secondary to acute pancreatitis, associated with decreased TNF-alpha levels, indicating CCR1 activation is an early event in systemic inflammatory response syndrome.","method":"CCR1 knockout mouse model with pancreatitis-associated lung injury readout and cytokine measurement","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype, replicated by pharmacological blockade studies","pmids":["9329966"],"is_preprint":false},{"year":1997,"finding":"MCP-2 (CCL8) uses CCR1 and CCR2B as functional receptors, as demonstrated by high-affinity 125I-MCP-2 binding to CCR1-transfected HEK293 cells and MCP-2-induced chemotaxis of CCR1-transfected cells.","method":"Radioligand binding assay and chemotaxis assay using receptor-transfected cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct binding assay with transfected cells plus functional chemotaxis validation","pmids":["9115216"],"is_preprint":false},{"year":1998,"finding":"Natural N-terminal truncation of RANTES (producing RANTES(3-68)) abolishes its ability to signal through CCR1 and CCR3 (calcium mobilization) while retaining CCR5 activity, demonstrating that the N-terminal domain of RANTES is essential for CCR1 activation.","method":"Calcium mobilization assay in receptor-transfected cells; chemotaxis inhibition assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — receptor-transfected cell assay with recombinant protein variants, multiple functional readouts","pmids":["9565366"],"is_preprint":false},{"year":1998,"finding":"Small molecule 4-hydroxypiperidine compounds act as functional CCR1 antagonists, inhibiting MIP-1alpha-induced extracellular acidification and Ca2+ mobilization without intrinsic agonist activity, and blocking MIP-1alpha- and RANTES-induced migration of PBMCs.","method":"Competitive radioligand binding (Scatchard analysis), extracellular acidification assay, Ca2+ mobilization assay, PBMC chemotaxis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple in vitro functional assays with defined pharmacology","pmids":["9624164"],"is_preprint":false},{"year":1999,"finding":"IFN-gamma treatment of human neutrophils causes rapid upregulation of CCR1 and CCR3 mRNA and induces functional CCR1 expression, enabling neutrophils to bind MCP-3 and migrate toward MIP-1alpha, RANTES, MCP-3, MIP-5/HCC2, and eotaxin — responses not seen in untreated neutrophils.","method":"mRNA expression (RT-PCR), radioligand binding assay, chemotaxis assay with receptor-specific blocking antibodies and antagonists","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding site measurement plus functional chemotaxis with receptor-specific inhibition","pmids":["9886422"],"is_preprint":false},{"year":1999,"finding":"CCR1 deficiency in mice enhances Th1 immune responses during nephrotoxic nephritis and increases renal T cell and macrophage recruitment; MIP-1alpha but not RANTES binds CCR1 and induces chemotaxis in CCR1-overexpressing transfected cells.","method":"CCR1 knockout mouse model, nephritis disease readout (proteinuria, BUN, crescent formation), reciprocal binding assay with transfected cells","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — KO with defined phenotype plus direct receptor binding validation with transfected cells","pmids":["10587518"],"is_preprint":false},{"year":2000,"finding":"CCR1 deletion in mice produces significant prolongation of cardiac allograft survival across multiple MHC-mismatch models, and transfer of CD4+ T cells from long-term tolerant CCR1-/- recipients prolongs allograft survival in naive recipients, demonstrating CCR1 is required for acute and chronic allograft rejection.","method":"CCR1 knockout mouse model, heterotopic cardiac transplantation across 4 genetic models, adoptive T cell transfer","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple independent transplant models and adoptive transfer validation","pmids":["10619859"],"is_preprint":false},{"year":2000,"finding":"CCR1 is expressed as a functional receptor on human platelets (confirmed by immunoprecipitation, Western blot, and flow cytometry), and CCR1 ligands including MIP-1alpha activate platelets to produce Ca2+ signals, aggregation, and granule content release, partly via ADP release and dependent on cell-surface heparan/chondroitin sulfate.","method":"Immunoprecipitation, Western blot, flow cytometry, Ca2+ mobilization assay, platelet aggregation assay, glycosaminoglycan cleavage experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods confirming functional receptor expression and mechanism","pmids":["11110672"],"is_preprint":false},{"year":2000,"finding":"CCR1 expression on primary mouse astrocytes is specifically upregulated at the transcriptional level by TGFbeta1 in a concentration- and time-dependent manner, resulting in increased CCR1 protein and augmented astrocyte migration toward MIP-1alpha.","method":"RT-PCR, mRNA half-life measurement, Western blot, chemotaxis assay","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 — direct mechanistic link between TGFbeta1, transcriptional upregulation of CCR1, and functional chemotaxis; single lab","pmids":["10696139"],"is_preprint":false},{"year":2000,"finding":"CCR1 deletion results in absence of airway remodeling (goblet cell hyperplasia and subepithelial fibrosis) in fungal allergic airway disease, associated with higher IFN-gamma and lower IL-4, IL-13, and Th2-inducible chemokines, identifying CCR1 as a major contributor to Th2-driven airway remodeling.","method":"CCR1 knockout mouse model, Aspergillus fumigatus sensitization/challenge model, histology, cytokine measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined histological and cytokine phenotype","pmids":["10903765"],"is_preprint":false},{"year":2000,"finding":"CCR1 activation and desensitization are regulated by phosphorylation of specific serine/threonine residues in the cytoplasmic tail (S2 and S3 regions); alanine substitution abolishes receptor phosphorylation and desensitization of G protein coupling but not of Ca2+ mobilization. CXCR1 and CXCR2 cross-phosphorylate and cross-desensitize CCR1, while CCR1 cross-phosphorylates CXCR2 but not CXCR1.","method":"Stable transfection of epitope-tagged CCR1 in RBL-2H3 cells, phosphorylation assays, GTPase stimulation assay, Ca2+ mobilization, alanine-scanning mutagenesis, co-expression with CXCR1/CXCR2","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with multiple functional assays in defined cell system","pmids":["10734056"],"is_preprint":false},{"year":2001,"finding":"CCR1 blockade with the small-molecule antagonist BX471 reduces interstitial macrophage and lymphocyte infiltration by 40-60% and substantially reduces renal fibrosis (collagen I, interstitial volume) after unilateral ureter obstruction in mice, even with late-onset treatment.","method":"Pharmacological antagonism with BX471 in mouse UUO model, histology, FACS, mRNA analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — pharmacologic blockade with defined cellular and fibrotic phenotype readout, multiple timepoints","pmids":["11805137"],"is_preprint":false},{"year":2002,"finding":"CCL5/RANTES-induced mast cell migration is mediated by both CCR1 and CCR4, as partial blockade of either receptor alone reduces migration and complete inhibition requires simultaneous blockade of both receptors.","method":"Receptor expression by flow cytometry, chemotaxis assay with receptor-specific blocking antibodies","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, antibody-based inhibition of chemotaxis","pmids":["12270118"],"is_preprint":false},{"year":2003,"finding":"Trophoblasts acquire CCR1 expression as they differentiate into invasive extravillous trophoblasts (EVTs) in a process dependent on oxygen tension; CCR1 ligands RANTES and MIP-1alpha produced in decidual tissue promote EVT migration in vitro, establishing a chemokine-CCR1 axis in trophoblast invasion.","method":"Immunohistochemistry, villous explant culture, EVT isolation, in vitro migration assay, RT-PCR, O2 tension manipulation","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization with functional migration consequence in primary cells; single lab","pmids":["14530297"],"is_preprint":false},{"year":2003,"finding":"CCR1 is expressed on human hepatoma cell lines but not normal liver, and its CCR1 ligands (CCL3, CCL4, CCL5) inhibit forskolin-induced cAMP elevation, demonstrating functional Gi-coupled CCR1 signaling. CCL3 production by hepatoma cells is induced by IL-1alpha and IL-1beta, suggesting an autocrine/paracrine CCL3-CCR1 loop.","method":"RT-PCR, immunohistochemistry, cAMP assay in hepatoma cell lines, ELISA for CCL3","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 — functional Gi signaling assay plus cytokine induction; single lab","pmids":["12651617"],"is_preprint":false},{"year":2004,"finding":"CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction; adoptive transfer of CCR1-deficient macrophages and T cells into wild-type mice confirms CCR1 on leukocytes is required for their recruitment to obstructed kidneys.","method":"CCR1 and CCR5 knockout mice, UUO model, flow cytometry, adoptive transfer of labeled leukocytes, pharmacological blockade with BX471","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 — KO plus adoptive transfer (reciprocal experiment) plus pharmacological validation","pmids":["14747380"],"is_preprint":false},{"year":2004,"finding":"CCR1 expressed on osteoclast (OC) precursors is upregulated by RANKL, and CCR1 ligands (MIP-1alpha, RANTES, MCP-3) stimulate OC precursor chemotaxis, enhance RANKL-induced OC formation through a RANKL-dependent but RANK-expression-independent pathway, and increase OC motility without altering resorption or survival.","method":"RT-PCR, chemotaxis assay, osteoclastogenesis assay with RAW264.7 and primary marrow cells, motility/resorption assays, ELISA","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays in primary cells and cell lines","pmids":["15537451"],"is_preprint":false},{"year":2004,"finding":"HCMV infection inhibits immature DC migration by internalizing CCR1 and CCR5 from the cell surface; this effect is mediated by early viral replicative events and by HCMV-induced secretion of CCL3, CCL4, and CCL5, as neutralizing antibodies against these chemokines reduce CCR1 downregulation and restore DC migration by ~60%.","method":"Flow cytometry for receptor surface expression, DC migration assay, neutralizing antibody treatment, viral replication inhibitors","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct mechanistic link between viral infection, receptor internalization, and functional migration; single lab","pmids":["15522919"],"is_preprint":false},{"year":2004,"finding":"LZIP (a transcription factor) binds directly to CCR1 (identified by yeast two-hybrid and confirmed by mammalian two-hybrid and co-immunoprecipitation); residues 21-260 of LZIP are essential for CCR1 interaction. LZIP overexpression selectively enhances Lkn-1/CCL15-induced but not MIP-1alpha-, RANTES-, or HCC-4-induced chemotaxis.","method":"Yeast two-hybrid, mammalian two-hybrid, co-immunoprecipitation, chemotaxis assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal binding validation plus functional selectivity; single lab","pmids":["15001559"],"is_preprint":false},{"year":2005,"finding":"Proinflammatory proteases and physiological fluids (including rheumatoid arthritis synovial fluid) cleave the extended N-terminal domains of CCL6, CCL9, CCL15, and CCL23, activating these 'alternative' CCR1 ligands up to 1000-fold in CCR1-mediated signaling and chemotaxis assays in vitro; the truncated forms are resistant to further cleavage.","method":"In vitro protease cleavage assay, CCR1 signaling assay, chemotaxis assay, mass spectrometry of synovial fluid chemokines","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of proteolytic activation with functional validation and physiological fluid confirmation","pmids":["15905581"],"is_preprint":false},{"year":2005,"finding":"MIP-1alpha mediates neutrophil migration in immune inflammation via CCR1 (not CCR5) by inducing sequential release of TNF-alpha and LTB4; CCR1-/- mice fail to respond to OVA or MIP-1alpha with neutrophil migration, while CCR5-/- mice respond normally.","method":"CCR1-/- and CCR5-/- mice, MIP-1alpha-/- mice, TNF receptor 1-/- mice, in vivo peritoneal immune inflammation model, LTB4/TNF-alpha measurement","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple KO strains defining pathway order","pmids":["15831559"],"is_preprint":false},{"year":2005,"finding":"MIP-1alpha promotes osteoclastogenesis and myeloma cell adhesion to stromal cells via CCR1 (as well as CCR5); blocking CCR1 with neutralizing antibodies or the CCR1-specific antagonist BX471 inhibits OCL formation and upregulation of beta1 integrin mRNA in myeloma cells, and reduces myeloma-stromal cell IL-6 production.","method":"RT-PCR, osteoclastogenesis assay, neutralizing antibodies to CCR1 and CCR5, CCR1-specific antagonist BX471, adhesion assay, IL-6 ELISA","journal":"Experimental hematology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal inhibitory approaches (antibody + small molecule antagonist) with functional readouts","pmids":["15730850"],"is_preprint":false},{"year":2005,"finding":"CCR1 acts downstream of NFAT2 in RANKL-stimulated osteoclastogenesis; RANKL induces CCR1 promoter activity in a cyclosporin A (CsA)-suppressible manner, and CCR1 siRNA or CCR1 antagonist Met-RANTES inhibit cell migration and multinucleated cell formation.","method":"Microarray, quantitative RT-PCR, luciferase reporter assay, siRNA knockdown, Boyden chamber migration assay, CsA inhibition of NFAT","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1-2 — promoter assay establishing NFAT2→CCR1 pathway, functional validation with siRNA and antagonist","pmids":["16355273"],"is_preprint":false},{"year":2005,"finding":"CCL23 promotes endothelial cell migration and angiogenesis through CCR1; pertussis toxin or anti-CCR1 antibody completely inhibits CCL23-induced endothelial cell migration, and CCL23 does not promote migration of CCR1-negative HT1080 cells.","method":"Chemotaxis assay, CAM angiogenesis assay, pertussis toxin treatment, anti-CCR1 antibody blocking, CCR1-negative control cells","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 — functional receptor identification via pertussis toxin and antibody blockade plus CCR1-negative control; single lab","pmids":["15927850"],"is_preprint":false},{"year":2006,"finding":"The predicted 3D structure of CCR1 identified Tyr-113, Tyr-114 (TM3) and Ile-259 (TM6) as key residues for BX471 antagonist binding; 17 point mutants validated predictions through competitive ligand binding and chemotaxis assays.","method":"Computational structure prediction (MembStruk), site-directed mutagenesis of 17 residues, competitive binding assay, chemotaxis assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 — mutagenesis-validated structure-function; computational model with experimental confirmation, single lab","pmids":["16837468"],"is_preprint":false},{"year":2007,"finding":"CCR1-expressing CD34+ immature myeloid cells (iMCs) migrate toward CCL9 (produced by SMAD4-deficient tumor epithelium), and CCR1 deletion prevents iMC accumulation at the tumor invasion front and suppresses tumor invasion in cis-Apc/Smad4 mutant mice.","method":"CCR1 knockout in tumor mouse model, immunohistochemistry for iMC markers (CD34, MMP9, MMP2), CCL9 expression analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic deletion with defined cellular and functional phenotype; published in high-impact journal","pmids":["17369830"],"is_preprint":false},{"year":2007,"finding":"CCR1 deficiency (Ccr1-/-) after myocardial infarction leads to diminished neutrophil infiltration, accelerated monocyte/lymphocyte infiltration, decreased apoptosis, increased proliferation, and earlier myofibroblast population, resulting in smaller infarcts and preserved left ventricular function.","method":"CCR1 knockout mouse model, LAD ligation MI model, Langendorff isolated heart preparation, immunohistochemistry, echocardiography","journal":"Journal of cellular and molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular and functional cardiac phenotypes","pmids":["18088392"],"is_preprint":false},{"year":2008,"finding":"CCR1 mediates macrophage and neutrophil infiltration into the kidney after renal ischemia-reperfusion injury; CCR1-/- mice have 35% fewer neutrophils and 45% fewer macrophages in injured kidneys, and CCR1-/- injured kidneys have reduced CCL3 and CCL5 levels, suggesting a CCR1-dependent positive feedback loop for leukocyte infiltration.","method":"CCR1 knockout mice, pharmacological blockade with BX471, flow cytometry, chemokine ELISA","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological evidence with defined cellular phenotype","pmids":["19050287"],"is_preprint":false},{"year":2010,"finding":"Overexpression of CCR1 in mesenchymal stem cells (MSCs) dramatically increases chemokine-induced migration and protects MSCs from apoptosis in vitro; CCR1-MSCs accumulate in infarcted myocardium at higher levels, reduce infarct size and cardiomyocyte apoptosis, increase capillary density, and restore cardiac function after MI.","method":"CCR1 overexpression in MSCs, in vitro migration and apoptosis assays, intramyocardial injection after coronary artery ligation, histology, echocardiography","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function with in vitro and in vivo validation, multiple functional readouts","pmids":["20378860"],"is_preprint":false},{"year":2010,"finding":"CCR1 deletion in mice causes osteopenia due to impaired osteoclast and osteoblast function; Ccr1-/- osteoclasts show abrogated cell fusion and no osteolytic activity with reduced RANK expression, and Ccr1-/- osteoblasts fail to support osteoclastogenesis due to reduced RANKL expression, establishing CCR1 in osteoclast-osteoblast cross-talk via RANK-RANKL axis.","method":"CCR1 knockout mice, bone densitometry, osteoclastogenesis assay, mineralized nodule formation, RT-PCR, co-culture experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — KO with defined cellular mechanism including co-culture epistasis","pmids":["20571024"],"is_preprint":false},{"year":2010,"finding":"CCR1 on human and mouse colon cancer cells (expressing CCL9/CCL15) recruits CCR1+ CD34+ Gr-1- immature myeloid cells that produce MMP2 and MMP9 to promote liver metastasis; genetic deletion of CCR1 or MMP2/MMP9 in the host dramatically suppresses metastatic outgrowth, and CCR1 antagonist BL5923 blocks iMC accumulation and prolongs survival.","method":"CCR1 knockout mouse model, liver dissemination model, immunohistochemistry, CCR1 antagonist treatment, survival analysis","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological evidence in vivo with defined cellular mechanism","pmids":["20616008"],"is_preprint":false},{"year":2012,"finding":"Neutrophil Ccr1 amplifies late renal immunopathology in invasive candidiasis by mediating excessive neutrophil recruitment from blood to kidney; Ccr1-/- mice have selectively impaired neutrophil accumulation in the kidney at late timepoints, improved renal function and survival without affecting fungal burden; adoptive transfer of mixed Ccr1+/+ and Ccr1-/- neutrophils confirms cell-autonomous CCR1-dependent trafficking.","method":"CCR1 knockout mice, candidiasis model, flow cytometry, adoptive transfer of mixed donor neutrophils, ex vivo chemotaxis assay","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — KO with adoptive transfer (cell-autonomous validation) and functional outcome","pmids":["22916017"],"is_preprint":false},{"year":2013,"finding":"CCR1 exhibits constitutive activity leading to basal cAMP inhibition, increased F-actin, and basal leukocyte migration; constitutive receptor phosphorylation recruits beta-arrestin-2 and drives G protein-independent receptor internalization. CCR1 simultaneously engages Gαi and beta-arrestin-2 in a multiprotein complex, and pertussis toxin-insensitive chemokine uptake suggests a scavenging function via the CCR1·beta-arrestin-2 complex.","method":"cAMP assay, F-actin measurement, migration assay, co-immunoprecipitation of CCR1/Gαi/beta-arrestin-2 complex, receptor internalization assay, pertussis toxin treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple functional assays demonstrating constitutive activity mechanism with complex biochemistry","pmids":["24056371"],"is_preprint":false},{"year":2013,"finding":"CCR1/CCL5 interaction in taxane-resistant prostate cancer cells (PC3PR) promotes invasion by activating ERK1/2 and Rac1/cdc42 signaling and increasing secretion of MMP-2 and MMP-9; CCR1 siRNA knockdown reduces all these effects and decreases invasion in Matrigel assay.","method":"siRNA knockdown, Western blot for p-ERK1/2 and Rac1/cdc42, MMP-2/9 secretion assay, Matrigel invasion assay, MEK1/2 inhibitor","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA KD with defined signaling pathway and functional invasion readout; single lab","pmids":["23876400"],"is_preprint":false},{"year":2013,"finding":"TNFα and IL-1β induce CCL3 expression in nucleus pulposus cells via NF-κB (p65/IKKβ), MAPK, and C/EBPβ signaling; CCL3-conditioned medium promotes macrophage migration that is blocked by a CCR1 antagonist, establishing the CCL3-CCR1 axis in macrophage infiltration in disc degeneration.","method":"Transfection/reporter assay, gain- and loss-of-function for p65/C/EBPβ/p50, lentiviral shRNA (shp65, shIKKβ), Transwell migration assay with CCR1 antagonist","journal":"Arthritis and rheumatism","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with multiple genetic tools plus functional CCR1-dependent migration; single lab","pmids":["23233369"],"is_preprint":false},{"year":2018,"finding":"CXCL4/Platelet Factor 4 acts as an agonist of CCR1, inducing CCR1 endocytosis and chemotaxis in CCR1-expressing transfectants and primary human monocytes via a pertussis toxin-sensitive, glycosaminoglycan-dependent mechanism; CCR1 antagonist blocks CXCL4-induced monocyte chemotaxis.","method":"Transfected cell migration assay, CCR1 endocytosis assay, pertussis toxin treatment, chondroitinase ABC treatment, CCR1 antagonist blockade, primary human monocyte migration","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1-2 — receptor transfectant validation plus primary cell confirmation with multiple mechanistic interventions","pmids":["29930254"],"is_preprint":false},{"year":2020,"finding":"CCR1 activation promotes neuroinflammation after intracerebral hemorrhage via a CCR1/TPR1/ERK1/2 signaling pathway; CCR1 inhibition with Met-RANTES decreases CCR1, TPR1, p-ERK, TNF-α, and IL-1β expression, and these effects are reversed by ERK1/2 activator ceramide C6; TPR1 CRISPR knockdown reverses the neurological effects of rCCL5-induced CCR1 activation.","method":"Mouse ICH model, intranasal Met-RANTES, Rac1/ERK1/2 pathway intervention, TPR1 CRISPR, Western blot, immunofluorescence","journal":"Neurotherapeutics","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo pharmacological and genetic pathway dissection; single lab","pmids":["31898284"],"is_preprint":false},{"year":2020,"finding":"Omental macrophages secrete CCL6 (mouse) and CCL23 (human) that promote ovarian cancer migration and colonization via CCR1; CCL6/CCL23 activate ERK1/2 and PI3K signaling in ovarian cancer cells; macrophage depletion and CCR1 inhibition both reduce omental colonization.","method":"RNA-sequencing of omental macrophages, macrophage depletion, CCL6/CCL23 knockdown/rescue, CCR1 inhibitor treatment, in vivo omental colonization assay, signaling pathway inhibitors","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological interventions with in vivo colonization readout","pmids":["32963283"],"is_preprint":false},{"year":2021,"finding":"Cryo-EM structures of the CCR1-Gi complex (2.6-2.9 Å) bound to different N-terminal truncations of CCL15 reveal that conformational change of Tyr291 (Y291^7.43) triggers polar network rearrangement in the orthosteric binding pocket and allosterically regulates beta-arrestin signaling; different CCL15 truncations act as balanced or biased agonists, identifying a structural basis for natural biased signaling at CCR1.","method":"Cryo-EM structure determination (3 structures), pharmacological characterization, computational studies, mutagenesis","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure at near-atomic resolution combined with pharmacological and computational validation","pmids":["34949837"],"is_preprint":false},{"year":2021,"finding":"The CCL6-CCR1 axis in hematopoietic stem cells (HSCs) promotes eosinophil differentiation and allergic airway inflammation; CCL6 (produced by eosinophils) acts on CCR1 on HSCs to drive eosinophil differentiation, and CCR1 antagonist BX471 markedly decreases eosinophil differentiation and airway inflammation.","method":"Ccl6 knockout mice, OVA challenge model, bone marrow analysis, CCR1 antagonist BX471, flow cytometry","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 2 — KO plus pharmacological blockade with defined cellular mechanism in HSCs","pmids":["33640900"],"is_preprint":false},{"year":2022,"finding":"CCR1 and CCR5 on myeloid cells and their precursors mediate cancer-induced MDSC differentiation; tumor-derived factors induce CCL3 and CCL4 in HSPCs that autocrinally engage CCR1 and CCR5 to drive MDSC differentiation (not chemotaxis); silencing CCR1/CCR5 repolarizes PMN-MDSCs into tumoricidal neutrophils and inhibits tumor progression.","method":"4PD nanoparticle-mediated in vivo gene silencing of CCR1/CCR5, flow cytometry, transcriptome analysis, cytokine bead arrays, in vitro HSPC differentiation assay with CCR1/CCR5-deficient mice and human cord blood HSPCs","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 2 — in vivo silencing with in vitro mechanistic validation across multiple genetic backgrounds and human cells","pmids":["35064009"],"is_preprint":false}],"current_model":"CCR1 is a constitutively active, Gαi-coupled, seven-transmembrane chemokine receptor that binds multiple CC chemokines (including CCL3/MIP-1α, CCL5/RANTES, CCL7/MCP-2, CCL15, CCL23, and others, the potency of which can be dramatically enhanced by proteolytic N-terminal processing), and whose activation drives leukocyte chemotaxis, osteoclastogenesis, and myeloid cell differentiation via Gαi-dependent signaling; simultaneously, CCR1 forms a complex with β-arrestin-2 for G protein-independent constitutive internalization/scavenging, and its structural basis for biased versus balanced signaling has been resolved by cryo-EM, revealing that conformational change of Tyr291 allosterically gates β-arrestin pathway engagement."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing CCR1 as a functional chemokine receptor for MIP-1α and RANTES whose deletion protects against systemic inflammatory injury resolved the question of whether CCR1 has a non-redundant role in leukocyte-driven inflammation in vivo.","evidence":"CCR1 knockout mice with pancreatitis-associated lung injury; radioligand binding and chemotaxis in CCR1-transfected cells","pmids":["9329966","9115216"],"confidence":"High","gaps":["Downstream signaling pathways not yet defined","Relative contribution of individual ligands to disease phenotype unknown"]},{"year":1998,"claim":"Demonstrating that the RANTES N-terminus is essential for CCR1 activation and that small-molecule antagonists can block CCR1 signaling established the pharmacological tractability of CCR1 and the structural determinants of ligand recognition.","evidence":"Truncated RANTES variants in calcium mobilization and chemotaxis assays; 4-hydroxypiperidine antagonists in binding, acidification, calcium, and migration assays","pmids":["9565366","9624164"],"confidence":"High","gaps":["No receptor structure available","Mechanism of antagonist binding not resolved at atomic level"]},{"year":2000,"claim":"Identification of phosphorylation-dependent desensitization, cross-desensitization by CXCR1/CXCR2, and functional CCR1 expression on platelets and astrocytes broadened the receptor's signaling regulation and cellular context beyond classical leukocyte chemotaxis.","evidence":"Alanine-scanning mutagenesis with GTPase/Ca²⁺ assays in RBL-2H3 cells; immunoprecipitation and aggregation assays on human platelets; TGFβ1-induced CCR1 upregulation in astrocytes","pmids":["10734056","11110672","10696139"],"confidence":"High","gaps":["Kinases responsible for CCR1 phosphorylation not identified","In vivo relevance of platelet CCR1 not tested"]},{"year":2001,"claim":"Pharmacological CCR1 blockade with BX471 reducing renal fibrosis after ureteral obstruction, later validated by CCR1 knockout and adoptive transfer, established that CCR1 on leukocytes is the primary driver of inflammatory cell recruitment leading to organ fibrosis.","evidence":"BX471 antagonist in mouse UUO model; CCR1/CCR5 knockout comparison with adoptive transfer of CCR1-deficient leukocytes","pmids":["11805137","14747380"],"confidence":"High","gaps":["Whether CCR1 on resident renal cells contributes was not fully excluded","Fibrotic signaling downstream of CCR1 on recruited cells not dissected"]},{"year":2005,"claim":"Discovery that proteolytic N-terminal truncation of CCL15 and CCL23 enhances CCR1 potency up to 1000-fold, and that NFAT2 transcriptionally activates CCR1 during RANKL-induced osteoclastogenesis, defined two key regulatory layers — extracellular ligand processing and transcriptional control — governing CCR1-mediated responses.","evidence":"In vitro protease cleavage with mass spectrometry and CCR1 signaling/chemotaxis assays; CCR1 promoter-luciferase with CsA inhibition and siRNA in osteoclast precursors","pmids":["15905581","16355273"],"confidence":"High","gaps":["In vivo relevance of truncated ligand forms not established in genetic models","Full promoter regulatory elements for CCR1 not mapped"]},{"year":2005,"claim":"Genetic epistasis using CCR1−/−, CCR5−/−, and MIP-1α−/− mice demonstrated that CCR1 (not CCR5) mediates MIP-1α-driven neutrophil migration via sequential TNF-α and LTB4 release, resolving receptor-specific signaling hierarchy in immune inflammation.","evidence":"Multiple knockout strains in peritoneal inflammation model with TNF-α/LTB4 measurement","pmids":["15831559"],"confidence":"High","gaps":["Whether this TNF-α→LTB4 cascade applies in all tissues not tested","Direct biochemical link between CCR1 and TNF-α secretion machinery unknown"]},{"year":2007,"claim":"Showing that CCR1-expressing CD34⁺ immature myeloid cells are recruited to the tumor invasion front via CCL9 and that CCR1 deletion suppresses tumor invasion established CCR1 as a mediator of pro-tumorigenic myeloid cell recruitment.","evidence":"CCR1 knockout in cis-Apc/Smad4 mutant intestinal tumor mouse model with immunohistochemistry for CD34/MMP markers","pmids":["17369830"],"confidence":"High","gaps":["Human relevance of CCL9/CCR1 axis in tumor invasion not directly tested","Whether CCR1 on tumor cells themselves contributes was not dissected"]},{"year":2010,"claim":"CCR1 knockout in bone revealed that CCR1 regulates not only osteoclast fusion and motility but also osteoblast RANKL expression, establishing a dual role in osteoclast-osteoblast cross-talk via the RANK-RANKL axis.","evidence":"CCR1 knockout mice with bone densitometry, osteoclastogenesis, and osteoblast co-culture assays","pmids":["20571024"],"confidence":"High","gaps":["Intracellular signaling linking CCR1 to RANKL transcription in osteoblasts unknown","Whether CCR1 ligand identity differs in bone microenvironment not resolved"]},{"year":2013,"claim":"Demonstrating that CCR1 is constitutively active — with basal Gαi coupling, β-arrestin-2 recruitment, and receptor internalization — and that it simultaneously engages Gαi and β-arrestin-2 in a multiprotein complex revealed a scavenging function independent of classical G protein signaling.","evidence":"cAMP, F-actin, migration, and co-immunoprecipitation assays with pertussis toxin in CCR1-expressing cells","pmids":["24056371"],"confidence":"High","gaps":["Structural basis for constitutive activity not yet determined","Physiological relevance of constitutive scavenging in vivo not demonstrated"]},{"year":2021,"claim":"Cryo-EM structures of CCR1–Gαi with different CCL15 truncations at 2.6–2.9 Å resolved the structural basis for biased agonism: conformational change of Tyr291 rearranges a polar network that allosterically gates β-arrestin engagement, directly answering how ligand processing generates balanced versus biased signaling.","evidence":"Three cryo-EM structures with mutagenesis and pharmacological characterization","pmids":["34949837"],"confidence":"High","gaps":["No structure of CCR1–β-arrestin complex available","How Tyr291 conformational switch mechanistically propagates to intracellular surface not fully modeled"]},{"year":2022,"claim":"Establishing that tumor-derived factors induce autocrine CCL3/CCL4–CCR1/CCR5 signaling in HSPCs to drive MDSC differentiation (rather than chemotaxis) revealed a non-migratory, differentiation-instructive function of CCR1 in cancer immune evasion.","evidence":"In vivo nanoparticle-mediated gene silencing, HSPC differentiation assays in CCR1/CCR5-deficient mice and human cord blood cells","pmids":["35064009"],"confidence":"High","gaps":["Relative contribution of CCR1 versus CCR5 in MDSC differentiation not fully deconvolved","Downstream transcriptional programs linking CCR1 to myeloid fate specification not identified"]},{"year":null,"claim":"Key unresolved questions include the structural basis of the CCR1–β-arrestin-2 complex, the in vivo relevance of constitutive scavenging activity, and how CCR1 signaling mechanistically switches between chemotactic and differentiation-instructive outputs in hematopoietic progenitors.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No CCR1–β-arrestin complex structure","Kinases mediating CCR1 constitutive phosphorylation unknown","Transcriptional programs downstream of CCR1 in HSPCs not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,2,3,32,38]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[18]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,10,17,32,35]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,10,32,33,36,38]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,4,5,9,15,20,27,31,39,40]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[29,39,40]}],"complexes":[],"partners":["CCL3","CCL5","CCL15","CCL23","ARRB2","GNAI1","LZIP","CXCL4"],"other_free_text":[]},"mechanistic_narrative":"CCR1 is a Gαi-coupled seven-transmembrane chemokine receptor that binds multiple CC chemokines — including CCL3/MIP-1α, CCL5/RANTES, CCL7/MCP-3, CCL15, and CCL23 — to drive leukocyte chemotaxis, osteoclastogenesis, and myeloid cell differentiation in diverse inflammatory, fibrotic, and neoplastic contexts [PMID:9329966, PMID:9115216, PMID:15537451, PMID:35064009]. Ligand binding triggers Gαi-dependent signaling including calcium mobilization, cAMP inhibition, and ERK1/2 activation, while CCR1 simultaneously exhibits constitutive activity that recruits β-arrestin-2 for G protein-independent internalization and chemokine scavenging [PMID:24056371, PMID:10734056]. Proteolytic N-terminal processing of ligands such as CCL15 and CCL23 by inflammatory proteases can enhance CCR1 potency up to 1000-fold, and cryo-EM structures of the CCR1–Gαi complex revealed that conformational switching of Tyr291 allosterically gates β-arrestin pathway engagement, providing a structural basis for biased agonism [PMID:15905581, PMID:34949837]. In vivo, CCR1 on neutrophils, macrophages, and CD34⁺ immature myeloid cells mediates their recruitment to sites of inflammation, fibrosis, and tumor invasion, and CCR1 signaling on hematopoietic stem and progenitor cells drives eosinophil and MDSC differentiation through autocrine/paracrine chemokine loops [PMID:14747380, PMID:17369830, PMID:33640900, PMID:35064009]."},"prefetch_data":{"uniprot":{"accession":"P32246","full_name":"C-C chemokine receptor type 1","aliases":["HM145","LD78 receptor","Macrophage inflammatory protein 1-alpha receptor","MIP-1alpha-R","RANTES-R"],"length_aa":355,"mass_kda":41.2,"function":"Chemokine receptor that plays a crucial role in regulating immune cell migration, inflammation, and immune responses (PubMed:14991608). Contributes to the inflammatory response by recruiting immune cells, such as monocytes, macrophages, T-cells, and dendritic cells, to sites of inflammation for the clearance of pathogens and the resolution of tissue damage. When activated by its ligands including CCL3, CCL5-9, CCL13-16 and CCL23, triggers a signaling cascade within immune cells, leading to their migration towards the source of the chemokine (PubMed:15905581, PubMed:38417634). For example, mediates neutrophil migration after activation by CCL3 leading to the sequential release of TNF and leukotriene B4 (By similarity). Also mediates monocyte migration upon CXCL4 binding (PubMed:29930254). Activation by CCL5 results in neuroinflammation through the ERK1/2 signaling pathway (By similarity)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P32246/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCR1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCR1","total_profiled":1310},"omim":[{"mim_id":"612007","title":"CELIAC DISEASE, SUSCEPTIBILITY TO, 9; CELIAC9","url":"https://www.omim.org/entry/612007"},{"mim_id":"604836","title":"CHEMOKINE, CC MOTIF, RECEPTOR 4; CCR4","url":"https://www.omim.org/entry/604836"},{"mim_id":"604697","title":"CHEMOKINE, CC MOTIF, LIGAND 26; CCL26","url":"https://www.omim.org/entry/604697"},{"mim_id":"601834","title":"CHEMOKINE, CC MOTIF, RECEPTOR 8; CCR8","url":"https://www.omim.org/entry/601834"},{"mim_id":"601393","title":"CHEMOKINE, CC MOTIF, LIGAND 15; CCL15","url":"https://www.omim.org/entry/601393"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":40.1}],"url":"https://www.proteinatlas.org/search/CCR1"},"hgnc":{"alias_symbol":["CKR-1","MIP1aR","CD191"],"prev_symbol":["SCYAR1","CMKBR1"]},"alphafold":{"accession":"P32246","domains":[{"cath_id":"1.20.1070.10","chopping":"28-327","consensus_level":"high","plddt":89.5565,"start":28,"end":327}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P32246","model_url":"https://alphafold.ebi.ac.uk/files/AF-P32246-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P32246-F1-predicted_aligned_error_v6.png","plddt_mean":83.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCR1","jax_strain_url":"https://www.jax.org/strain/search?query=CCR1"},"sequence":{"accession":"P32246","fasta_url":"https://rest.uniprot.org/uniprotkb/P32246.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P32246/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P32246"}},"corpus_meta":[{"pmid":"17138939","id":"PMC_17138939","title":"Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice.","date":"2006","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17138939","citation_count":240,"is_preprint":false},{"pmid":"17369830","id":"PMC_17369830","title":"SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17369830","citation_count":233,"is_preprint":false},{"pmid":"11110672","id":"PMC_11110672","title":"Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11110672","citation_count":201,"is_preprint":false},{"pmid":"11805137","id":"PMC_11805137","title":"A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11805137","citation_count":192,"is_preprint":false},{"pmid":"10619859","id":"PMC_10619859","title":"Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection.","date":"2000","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10619859","citation_count":187,"is_preprint":false},{"pmid":"20378860","id":"PMC_20378860","title":"Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium.","date":"2010","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/20378860","citation_count":183,"is_preprint":false},{"pmid":"9886422","id":"PMC_9886422","title":"Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9886422","citation_count":168,"is_preprint":false},{"pmid":"23233369","id":"PMC_23233369","title":"Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1.","date":"2013","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/23233369","citation_count":167,"is_preprint":false},{"pmid":"15537451","id":"PMC_15537451","title":"CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.","date":"2004","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/15537451","citation_count":166,"is_preprint":false},{"pmid":"9329966","id":"PMC_9329966","title":"Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9329966","citation_count":162,"is_preprint":false},{"pmid":"20616008","id":"PMC_20616008","title":"Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20616008","citation_count":151,"is_preprint":false},{"pmid":"15905581","id":"PMC_15905581","title":"Proteolytic activation of alternative CCR1 ligands in inflammation.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15905581","citation_count":144,"is_preprint":false},{"pmid":"10587518","id":"PMC_10587518","title":"Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10587518","citation_count":126,"is_preprint":false},{"pmid":"15569315","id":"PMC_15569315","title":"CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.","date":"2004","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/15569315","citation_count":123,"is_preprint":false},{"pmid":"15831559","id":"PMC_15831559","title":"MIP-1alpha[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-alpha and LTB4.","date":"2005","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15831559","citation_count":122,"is_preprint":false},{"pmid":"9115216","id":"PMC_9115216","title":"Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9115216","citation_count":121,"is_preprint":false},{"pmid":"15730850","id":"PMC_15730850","title":"MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.","date":"2005","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/15730850","citation_count":121,"is_preprint":false},{"pmid":"17715391","id":"PMC_17715391","title":"MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17715391","citation_count":117,"is_preprint":false},{"pmid":"9565366","id":"PMC_9565366","title":"Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9565366","citation_count":116,"is_preprint":false},{"pmid":"23891973","id":"PMC_23891973","title":"Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.","date":"2013","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23891973","citation_count":112,"is_preprint":false},{"pmid":"9624164","id":"PMC_9624164","title":"Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9624164","citation_count":107,"is_preprint":false},{"pmid":"14747380","id":"PMC_14747380","title":"Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction.","date":"2004","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/14747380","citation_count":105,"is_preprint":false},{"pmid":"22916017","id":"PMC_22916017","title":"Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22916017","citation_count":98,"is_preprint":false},{"pmid":"14530297","id":"PMC_14530297","title":"Trophoblasts acquire a chemokine receptor, CCR1, as they differentiate towards invasive phenotype.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14530297","citation_count":97,"is_preprint":false},{"pmid":"10903765","id":"PMC_10903765","title":"Airway remodeling is absent in CCR1-/- mice during chronic fungal allergic airway disease.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10903765","citation_count":90,"is_preprint":false},{"pmid":"14734772","id":"PMC_14734772","title":"The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14734772","citation_count":87,"is_preprint":false},{"pmid":"22752444","id":"PMC_22752444","title":"RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans.","date":"2012","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22752444","citation_count":85,"is_preprint":false},{"pmid":"15927850","id":"PMC_15927850","title":"Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis.","date":"2005","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/15927850","citation_count":84,"is_preprint":false},{"pmid":"16837468","id":"PMC_16837468","title":"Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16837468","citation_count":83,"is_preprint":false},{"pmid":"16284949","id":"PMC_16284949","title":"Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16284949","citation_count":83,"is_preprint":false},{"pmid":"8884276","id":"PMC_8884276","title":"The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8884276","citation_count":81,"is_preprint":false},{"pmid":"11470772","id":"PMC_11470772","title":"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.","date":"2001","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11470772","citation_count":79,"is_preprint":false},{"pmid":"19050287","id":"PMC_19050287","title":"Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19050287","citation_count":77,"is_preprint":false},{"pmid":"23876400","id":"PMC_23876400","title":"CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling.","date":"2013","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/23876400","citation_count":77,"is_preprint":false},{"pmid":"32963283","id":"PMC_32963283","title":"Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32963283","citation_count":76,"is_preprint":false},{"pmid":"21332278","id":"PMC_21332278","title":"Spatiotemporal CCR1, CCL3(MIP-1α), CXCR4, CXCL12(SDF-1α) expression patterns in a rat spinal cord injury model of posttraumatic neuropathic pain.","date":"2011","source":"Journal of neurosurgery. Spine","url":"https://pubmed.ncbi.nlm.nih.gov/21332278","citation_count":76,"is_preprint":false},{"pmid":"14757698","id":"PMC_14757698","title":"Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.","date":"2004","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/14757698","citation_count":74,"is_preprint":false},{"pmid":"21747955","id":"PMC_21747955","title":"Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21747955","citation_count":72,"is_preprint":false},{"pmid":"29930254","id":"PMC_29930254","title":"CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29930254","citation_count":72,"is_preprint":false},{"pmid":"9616137","id":"PMC_9616137","title":"Interferon-gamma increases expression of chemokine receptors CCR1, CCR3, and CCR5, but not CXCR4 in monocytoid U937 cells.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9616137","citation_count":72,"is_preprint":false},{"pmid":"34949837","id":"PMC_34949837","title":"Identification and mechanism of G protein-biased ligands for chemokine receptor CCR1.","date":"2021","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/34949837","citation_count":70,"is_preprint":false},{"pmid":"17016504","id":"PMC_17016504","title":"Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17016504","citation_count":69,"is_preprint":false},{"pmid":"24056371","id":"PMC_24056371","title":"The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24056371","citation_count":68,"is_preprint":false},{"pmid":"12651617","id":"PMC_12651617","title":"Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12651617","citation_count":67,"is_preprint":false},{"pmid":"15522919","id":"PMC_15522919","title":"Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15522919","citation_count":67,"is_preprint":false},{"pmid":"9864143","id":"PMC_9864143","title":"CC chemokine receptors, CCR-1 and CCR-3, are potentially involved in antigen-presenting cell function of human peripheral blood monocyte-derived dendritic cells.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9864143","citation_count":66,"is_preprint":false},{"pmid":"33640900","id":"PMC_33640900","title":"Eosinophil-derived chemokine (hCCL15/23, mCCL6) interacts with CCR1 to promote eosinophilic airway inflammation.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33640900","citation_count":65,"is_preprint":false},{"pmid":"12270118","id":"PMC_12270118","title":"Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12270118","citation_count":65,"is_preprint":false},{"pmid":"11311066","id":"PMC_11311066","title":"Design, synthesis, and discovery of a novel CCR1 antagonist.","date":"2001","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11311066","citation_count":62,"is_preprint":false},{"pmid":"19050323","id":"PMC_19050323","title":"Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis.","date":"2008","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/19050323","citation_count":60,"is_preprint":false},{"pmid":"31898284","id":"PMC_31898284","title":"CCR1 Activation Promotes Neuroinflammation Through CCR1/TPR1/ERK1/2 Signaling Pathway After Intracerebral Hemorrhage in Mice.","date":"2020","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31898284","citation_count":59,"is_preprint":false},{"pmid":"18088392","id":"PMC_18088392","title":"Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction.","date":"2007","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18088392","citation_count":58,"is_preprint":false},{"pmid":"3302603","id":"PMC_3302603","title":"The effects of ADR1 and CCR1 gene dosage on the regulation of the glucose-repressible alcohol dehydrogenase from Saccharomyces cerevisiae.","date":"1987","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/3302603","citation_count":56,"is_preprint":false},{"pmid":"10734056","id":"PMC_10734056","title":"Regulation of the human chemokine receptor CCR1. Cross-regulation by CXCR1 and CXCR2.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10734056","citation_count":55,"is_preprint":false},{"pmid":"20870892","id":"PMC_20870892","title":"The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis.","date":"2010","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20870892","citation_count":54,"is_preprint":false},{"pmid":"35691078","id":"PMC_35691078","title":"The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35691078","citation_count":53,"is_preprint":false},{"pmid":"16374420","id":"PMC_16374420","title":"Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16374420","citation_count":52,"is_preprint":false},{"pmid":"16491201","id":"PMC_16491201","title":"Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice.","date":"2005","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/16491201","citation_count":51,"is_preprint":false},{"pmid":"17229070","id":"PMC_17229070","title":"Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage.","date":"2007","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/17229070","citation_count":49,"is_preprint":false},{"pmid":"20571024","id":"PMC_20571024","title":"Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20571024","citation_count":47,"is_preprint":false},{"pmid":"28855206","id":"PMC_28855206","title":"HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28855206","citation_count":47,"is_preprint":false},{"pmid":"10579830","id":"PMC_10579830","title":"Discovery of novel non-peptide CCR1 receptor antagonists.","date":"1999","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10579830","citation_count":47,"is_preprint":false},{"pmid":"10696139","id":"PMC_10696139","title":"TGFbeta1 selectively up-regulates CCR1 expression in primary murine astrocytes.","date":"2000","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/10696139","citation_count":45,"is_preprint":false},{"pmid":"12769747","id":"PMC_12769747","title":"CCR1 chemokine receptor antagonist.","date":"2003","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/12769747","citation_count":44,"is_preprint":false},{"pmid":"17914560","id":"PMC_17914560","title":"Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense.","date":"2007","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/17914560","citation_count":44,"is_preprint":false},{"pmid":"26058952","id":"PMC_26058952","title":"CCR1, an enzyme required for lignin biosynthesis in Arabidopsis, mediates cell proliferation exit for leaf development.","date":"2015","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26058952","citation_count":42,"is_preprint":false},{"pmid":"10910894","id":"PMC_10910894","title":"LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10910894","citation_count":41,"is_preprint":false},{"pmid":"17336272","id":"PMC_17336272","title":"Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17336272","citation_count":40,"is_preprint":false},{"pmid":"22350089","id":"PMC_22350089","title":"A knockout mutation in the lignin biosynthesis gene CCR1 explains a major QTL for acid detergent lignin content in Brassica napus seeds.","date":"2012","source":"TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik","url":"https://pubmed.ncbi.nlm.nih.gov/22350089","citation_count":40,"is_preprint":false},{"pmid":"25986216","id":"PMC_25986216","title":"A polymorphism in CCR1/CCR3 is associated with narcolepsy.","date":"2015","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25986216","citation_count":39,"is_preprint":false},{"pmid":"30720175","id":"PMC_30720175","title":"MiR-126-3p suppresses the growth, migration and invasion of NSCLC via targeting CCR1.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30720175","citation_count":38,"is_preprint":false},{"pmid":"16178722","id":"PMC_16178722","title":"BX471: a CCR1 antagonist with anti-inflammatory activity in man.","date":"2005","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16178722","citation_count":38,"is_preprint":false},{"pmid":"23059626","id":"PMC_23059626","title":"The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.","date":"2012","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/23059626","citation_count":38,"is_preprint":false},{"pmid":"15001559","id":"PMC_15001559","title":"Human LZIP binds to CCR1 and differentially affects the chemotactic activities of CCR1-dependent chemokines.","date":"2004","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15001559","citation_count":37,"is_preprint":false},{"pmid":"29895319","id":"PMC_29895319","title":"GWAS-identified CCR1 and IL10 loci contribute to M1 macrophage-predominant inflammation in Behçet's disease.","date":"2018","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29895319","citation_count":34,"is_preprint":false},{"pmid":"26383527","id":"PMC_26383527","title":"The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26383527","citation_count":34,"is_preprint":false},{"pmid":"12541321","id":"PMC_12541321","title":"Developmental changes in the expression of chemokine receptor CCR1 in the rat cerebellum.","date":"2003","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12541321","citation_count":34,"is_preprint":false},{"pmid":"16355273","id":"PMC_16355273","title":"CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration.","date":"2005","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/16355273","citation_count":32,"is_preprint":false},{"pmid":"14595653","id":"PMC_14595653","title":"CCR1 is an early and specific marker of Alzheimer's disease.","date":"2003","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/14595653","citation_count":32,"is_preprint":false},{"pmid":"24325454","id":"PMC_24325454","title":"Quercetin suppresses MIP-1α-induced adipose inflammation by downregulating its receptors CCR1/CCR5 and inhibiting inflammatory signaling.","date":"2013","source":"Journal of medicinal food","url":"https://pubmed.ncbi.nlm.nih.gov/24325454","citation_count":31,"is_preprint":false},{"pmid":"22364730","id":"PMC_22364730","title":"Effect of a CCR1 receptor antagonist on systemic trafficking of MSCs and polyethylene particle-associated bone loss.","date":"2012","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/22364730","citation_count":31,"is_preprint":false},{"pmid":"35399952","id":"PMC_35399952","title":"Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35399952","citation_count":30,"is_preprint":false},{"pmid":"11943214","id":"PMC_11943214","title":"Leukotactin-1/CCL15-induced chemotaxis signaling through CCR1 in HOS cells.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11943214","citation_count":30,"is_preprint":false},{"pmid":"35062973","id":"PMC_35062973","title":"Met-RANTES preserves the blood-brain barrier through inhibiting CCR1/SRC/Rac1 pathway after intracerebral hemorrhage in mice.","date":"2022","source":"Fluids and barriers of the CNS","url":"https://pubmed.ncbi.nlm.nih.gov/35062973","citation_count":30,"is_preprint":false},{"pmid":"29212252","id":"PMC_29212252","title":"C-C motif chemokine receptor 1 (CCR1) is a target of the EGF-AKT-mTOR-STAT3 signaling axis in breast cancer cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29212252","citation_count":30,"is_preprint":false},{"pmid":"24316469","id":"PMC_24316469","title":"The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells.","date":"2013","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24316469","citation_count":30,"is_preprint":false},{"pmid":"18560988","id":"PMC_18560988","title":"CCR1 antagonists.","date":"2008","source":"Molecular diversity","url":"https://pubmed.ncbi.nlm.nih.gov/18560988","citation_count":29,"is_preprint":false},{"pmid":"35219910","id":"PMC_35219910","title":"CCR1 antagonist ameliorates experimental autoimmune encephalomyelitis by inhibition of Th9/Th22-related markers in the brain and periphery.","date":"2022","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35219910","citation_count":29,"is_preprint":false},{"pmid":"34050704","id":"PMC_34050704","title":"CCL23 suppresses liver cancer progression through the CCR1/AKT/ESR1 feedback loop.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34050704","citation_count":28,"is_preprint":false},{"pmid":"17604006","id":"PMC_17604006","title":"CCR1 and CCR5 chemokine receptors are involved in fever induced by LPS (E. coli) and RANTES in rats.","date":"2007","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17604006","citation_count":28,"is_preprint":false},{"pmid":"35064009","id":"PMC_35064009","title":"CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35064009","citation_count":27,"is_preprint":false},{"pmid":"15086771","id":"PMC_15086771","title":"The chemokine receptor CCR1 is strongly up-regulated after skin injury but dispensable for wound healing.","date":"2004","source":"Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society","url":"https://pubmed.ncbi.nlm.nih.gov/15086771","citation_count":27,"is_preprint":false},{"pmid":"9336350","id":"PMC_9336350","title":"Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function.","date":"1997","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/9336350","citation_count":27,"is_preprint":false},{"pmid":"32463796","id":"PMC_32463796","title":"Cigarette smoke-induced lung inflammation in COPD mediated via CCR1/JAK/STAT /NF-κB pathway.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32463796","citation_count":25,"is_preprint":false},{"pmid":"26501423","id":"PMC_26501423","title":"CCL15/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26501423","citation_count":25,"is_preprint":false},{"pmid":"36630565","id":"PMC_36630565","title":"Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36630565","citation_count":24,"is_preprint":false},{"pmid":"27046081","id":"PMC_27046081","title":"CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer.","date":"2016","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27046081","citation_count":24,"is_preprint":false},{"pmid":"12574358","id":"PMC_12574358","title":"Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12574358","citation_count":24,"is_preprint":false},{"pmid":"16088077","id":"PMC_16088077","title":"Chemokine receptor CCR1: a new target for progressive kidney disease.","date":"2005","source":"American journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/16088077","citation_count":24,"is_preprint":false},{"pmid":"17312463","id":"PMC_17312463","title":"Treatment with BX471, a nonpeptide CCR1 antagonist, protects mice against acute pancreatitis-associated lung injury by modulating neutrophil recruitment.","date":"2007","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/17312463","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53723,"output_tokens":9608,"usd":0.152644},"stage2":{"model":"claude-opus-4-6","input_tokens":13545,"output_tokens":3209,"usd":0.221925},"total_usd":0.374569,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR1 (beta-chemokine receptor) binds MIP-1alpha and RANTES, and its genetic deletion protects mice from pulmonary inflammation secondary to acute pancreatitis, associated with decreased TNF-alpha levels, indicating CCR1 activation is an early event in systemic inflammatory response syndrome.\",\n      \"method\": \"CCR1 knockout mouse model with pancreatitis-associated lung injury readout and cytokine measurement\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, replicated by pharmacological blockade studies\",\n      \"pmids\": [\"9329966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MCP-2 (CCL8) uses CCR1 and CCR2B as functional receptors, as demonstrated by high-affinity 125I-MCP-2 binding to CCR1-transfected HEK293 cells and MCP-2-induced chemotaxis of CCR1-transfected cells.\",\n      \"method\": \"Radioligand binding assay and chemotaxis assay using receptor-transfected cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding assay with transfected cells plus functional chemotaxis validation\",\n      \"pmids\": [\"9115216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Natural N-terminal truncation of RANTES (producing RANTES(3-68)) abolishes its ability to signal through CCR1 and CCR3 (calcium mobilization) while retaining CCR5 activity, demonstrating that the N-terminal domain of RANTES is essential for CCR1 activation.\",\n      \"method\": \"Calcium mobilization assay in receptor-transfected cells; chemotaxis inhibition assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — receptor-transfected cell assay with recombinant protein variants, multiple functional readouts\",\n      \"pmids\": [\"9565366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Small molecule 4-hydroxypiperidine compounds act as functional CCR1 antagonists, inhibiting MIP-1alpha-induced extracellular acidification and Ca2+ mobilization without intrinsic agonist activity, and blocking MIP-1alpha- and RANTES-induced migration of PBMCs.\",\n      \"method\": \"Competitive radioligand binding (Scatchard analysis), extracellular acidification assay, Ca2+ mobilization assay, PBMC chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple in vitro functional assays with defined pharmacology\",\n      \"pmids\": [\"9624164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IFN-gamma treatment of human neutrophils causes rapid upregulation of CCR1 and CCR3 mRNA and induces functional CCR1 expression, enabling neutrophils to bind MCP-3 and migrate toward MIP-1alpha, RANTES, MCP-3, MIP-5/HCC2, and eotaxin — responses not seen in untreated neutrophils.\",\n      \"method\": \"mRNA expression (RT-PCR), radioligand binding assay, chemotaxis assay with receptor-specific blocking antibodies and antagonists\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding site measurement plus functional chemotaxis with receptor-specific inhibition\",\n      \"pmids\": [\"9886422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCR1 deficiency in mice enhances Th1 immune responses during nephrotoxic nephritis and increases renal T cell and macrophage recruitment; MIP-1alpha but not RANTES binds CCR1 and induces chemotaxis in CCR1-overexpressing transfected cells.\",\n      \"method\": \"CCR1 knockout mouse model, nephritis disease readout (proteinuria, BUN, crescent formation), reciprocal binding assay with transfected cells\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined phenotype plus direct receptor binding validation with transfected cells\",\n      \"pmids\": [\"10587518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR1 deletion in mice produces significant prolongation of cardiac allograft survival across multiple MHC-mismatch models, and transfer of CD4+ T cells from long-term tolerant CCR1-/- recipients prolongs allograft survival in naive recipients, demonstrating CCR1 is required for acute and chronic allograft rejection.\",\n      \"method\": \"CCR1 knockout mouse model, heterotopic cardiac transplantation across 4 genetic models, adoptive T cell transfer\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple independent transplant models and adoptive transfer validation\",\n      \"pmids\": [\"10619859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR1 is expressed as a functional receptor on human platelets (confirmed by immunoprecipitation, Western blot, and flow cytometry), and CCR1 ligands including MIP-1alpha activate platelets to produce Ca2+ signals, aggregation, and granule content release, partly via ADP release and dependent on cell-surface heparan/chondroitin sulfate.\",\n      \"method\": \"Immunoprecipitation, Western blot, flow cytometry, Ca2+ mobilization assay, platelet aggregation assay, glycosaminoglycan cleavage experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods confirming functional receptor expression and mechanism\",\n      \"pmids\": [\"11110672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR1 expression on primary mouse astrocytes is specifically upregulated at the transcriptional level by TGFbeta1 in a concentration- and time-dependent manner, resulting in increased CCR1 protein and augmented astrocyte migration toward MIP-1alpha.\",\n      \"method\": \"RT-PCR, mRNA half-life measurement, Western blot, chemotaxis assay\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mechanistic link between TGFbeta1, transcriptional upregulation of CCR1, and functional chemotaxis; single lab\",\n      \"pmids\": [\"10696139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR1 deletion results in absence of airway remodeling (goblet cell hyperplasia and subepithelial fibrosis) in fungal allergic airway disease, associated with higher IFN-gamma and lower IL-4, IL-13, and Th2-inducible chemokines, identifying CCR1 as a major contributor to Th2-driven airway remodeling.\",\n      \"method\": \"CCR1 knockout mouse model, Aspergillus fumigatus sensitization/challenge model, histology, cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined histological and cytokine phenotype\",\n      \"pmids\": [\"10903765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR1 activation and desensitization are regulated by phosphorylation of specific serine/threonine residues in the cytoplasmic tail (S2 and S3 regions); alanine substitution abolishes receptor phosphorylation and desensitization of G protein coupling but not of Ca2+ mobilization. CXCR1 and CXCR2 cross-phosphorylate and cross-desensitize CCR1, while CCR1 cross-phosphorylates CXCR2 but not CXCR1.\",\n      \"method\": \"Stable transfection of epitope-tagged CCR1 in RBL-2H3 cells, phosphorylation assays, GTPase stimulation assay, Ca2+ mobilization, alanine-scanning mutagenesis, co-expression with CXCR1/CXCR2\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with multiple functional assays in defined cell system\",\n      \"pmids\": [\"10734056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCR1 blockade with the small-molecule antagonist BX471 reduces interstitial macrophage and lymphocyte infiltration by 40-60% and substantially reduces renal fibrosis (collagen I, interstitial volume) after unilateral ureter obstruction in mice, even with late-onset treatment.\",\n      \"method\": \"Pharmacological antagonism with BX471 in mouse UUO model, histology, FACS, mRNA analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacologic blockade with defined cellular and fibrotic phenotype readout, multiple timepoints\",\n      \"pmids\": [\"11805137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL5/RANTES-induced mast cell migration is mediated by both CCR1 and CCR4, as partial blockade of either receptor alone reduces migration and complete inhibition requires simultaneous blockade of both receptors.\",\n      \"method\": \"Receptor expression by flow cytometry, chemotaxis assay with receptor-specific blocking antibodies\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, antibody-based inhibition of chemotaxis\",\n      \"pmids\": [\"12270118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Trophoblasts acquire CCR1 expression as they differentiate into invasive extravillous trophoblasts (EVTs) in a process dependent on oxygen tension; CCR1 ligands RANTES and MIP-1alpha produced in decidual tissue promote EVT migration in vitro, establishing a chemokine-CCR1 axis in trophoblast invasion.\",\n      \"method\": \"Immunohistochemistry, villous explant culture, EVT isolation, in vitro migration assay, RT-PCR, O2 tension manipulation\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional migration consequence in primary cells; single lab\",\n      \"pmids\": [\"14530297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCR1 is expressed on human hepatoma cell lines but not normal liver, and its CCR1 ligands (CCL3, CCL4, CCL5) inhibit forskolin-induced cAMP elevation, demonstrating functional Gi-coupled CCR1 signaling. CCL3 production by hepatoma cells is induced by IL-1alpha and IL-1beta, suggesting an autocrine/paracrine CCL3-CCR1 loop.\",\n      \"method\": \"RT-PCR, immunohistochemistry, cAMP assay in hepatoma cell lines, ELISA for CCL3\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional Gi signaling assay plus cytokine induction; single lab\",\n      \"pmids\": [\"12651617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction; adoptive transfer of CCR1-deficient macrophages and T cells into wild-type mice confirms CCR1 on leukocytes is required for their recruitment to obstructed kidneys.\",\n      \"method\": \"CCR1 and CCR5 knockout mice, UUO model, flow cytometry, adoptive transfer of labeled leukocytes, pharmacological blockade with BX471\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO plus adoptive transfer (reciprocal experiment) plus pharmacological validation\",\n      \"pmids\": [\"14747380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCR1 expressed on osteoclast (OC) precursors is upregulated by RANKL, and CCR1 ligands (MIP-1alpha, RANTES, MCP-3) stimulate OC precursor chemotaxis, enhance RANKL-induced OC formation through a RANKL-dependent but RANK-expression-independent pathway, and increase OC motility without altering resorption or survival.\",\n      \"method\": \"RT-PCR, chemotaxis assay, osteoclastogenesis assay with RAW264.7 and primary marrow cells, motility/resorption assays, ELISA\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays in primary cells and cell lines\",\n      \"pmids\": [\"15537451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"HCMV infection inhibits immature DC migration by internalizing CCR1 and CCR5 from the cell surface; this effect is mediated by early viral replicative events and by HCMV-induced secretion of CCL3, CCL4, and CCL5, as neutralizing antibodies against these chemokines reduce CCR1 downregulation and restore DC migration by ~60%.\",\n      \"method\": \"Flow cytometry for receptor surface expression, DC migration assay, neutralizing antibody treatment, viral replication inhibitors\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mechanistic link between viral infection, receptor internalization, and functional migration; single lab\",\n      \"pmids\": [\"15522919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LZIP (a transcription factor) binds directly to CCR1 (identified by yeast two-hybrid and confirmed by mammalian two-hybrid and co-immunoprecipitation); residues 21-260 of LZIP are essential for CCR1 interaction. LZIP overexpression selectively enhances Lkn-1/CCL15-induced but not MIP-1alpha-, RANTES-, or HCC-4-induced chemotaxis.\",\n      \"method\": \"Yeast two-hybrid, mammalian two-hybrid, co-immunoprecipitation, chemotaxis assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding validation plus functional selectivity; single lab\",\n      \"pmids\": [\"15001559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Proinflammatory proteases and physiological fluids (including rheumatoid arthritis synovial fluid) cleave the extended N-terminal domains of CCL6, CCL9, CCL15, and CCL23, activating these 'alternative' CCR1 ligands up to 1000-fold in CCR1-mediated signaling and chemotaxis assays in vitro; the truncated forms are resistant to further cleavage.\",\n      \"method\": \"In vitro protease cleavage assay, CCR1 signaling assay, chemotaxis assay, mass spectrometry of synovial fluid chemokines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of proteolytic activation with functional validation and physiological fluid confirmation\",\n      \"pmids\": [\"15905581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MIP-1alpha mediates neutrophil migration in immune inflammation via CCR1 (not CCR5) by inducing sequential release of TNF-alpha and LTB4; CCR1-/- mice fail to respond to OVA or MIP-1alpha with neutrophil migration, while CCR5-/- mice respond normally.\",\n      \"method\": \"CCR1-/- and CCR5-/- mice, MIP-1alpha-/- mice, TNF receptor 1-/- mice, in vivo peritoneal immune inflammation model, LTB4/TNF-alpha measurement\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple KO strains defining pathway order\",\n      \"pmids\": [\"15831559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MIP-1alpha promotes osteoclastogenesis and myeloma cell adhesion to stromal cells via CCR1 (as well as CCR5); blocking CCR1 with neutralizing antibodies or the CCR1-specific antagonist BX471 inhibits OCL formation and upregulation of beta1 integrin mRNA in myeloma cells, and reduces myeloma-stromal cell IL-6 production.\",\n      \"method\": \"RT-PCR, osteoclastogenesis assay, neutralizing antibodies to CCR1 and CCR5, CCR1-specific antagonist BX471, adhesion assay, IL-6 ELISA\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal inhibitory approaches (antibody + small molecule antagonist) with functional readouts\",\n      \"pmids\": [\"15730850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCR1 acts downstream of NFAT2 in RANKL-stimulated osteoclastogenesis; RANKL induces CCR1 promoter activity in a cyclosporin A (CsA)-suppressible manner, and CCR1 siRNA or CCR1 antagonist Met-RANTES inhibit cell migration and multinucleated cell formation.\",\n      \"method\": \"Microarray, quantitative RT-PCR, luciferase reporter assay, siRNA knockdown, Boyden chamber migration assay, CsA inhibition of NFAT\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter assay establishing NFAT2→CCR1 pathway, functional validation with siRNA and antagonist\",\n      \"pmids\": [\"16355273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL23 promotes endothelial cell migration and angiogenesis through CCR1; pertussis toxin or anti-CCR1 antibody completely inhibits CCL23-induced endothelial cell migration, and CCL23 does not promote migration of CCR1-negative HT1080 cells.\",\n      \"method\": \"Chemotaxis assay, CAM angiogenesis assay, pertussis toxin treatment, anti-CCR1 antibody blocking, CCR1-negative control cells\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional receptor identification via pertussis toxin and antibody blockade plus CCR1-negative control; single lab\",\n      \"pmids\": [\"15927850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The predicted 3D structure of CCR1 identified Tyr-113, Tyr-114 (TM3) and Ile-259 (TM6) as key residues for BX471 antagonist binding; 17 point mutants validated predictions through competitive ligand binding and chemotaxis assays.\",\n      \"method\": \"Computational structure prediction (MembStruk), site-directed mutagenesis of 17 residues, competitive binding assay, chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis-validated structure-function; computational model with experimental confirmation, single lab\",\n      \"pmids\": [\"16837468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCR1-expressing CD34+ immature myeloid cells (iMCs) migrate toward CCL9 (produced by SMAD4-deficient tumor epithelium), and CCR1 deletion prevents iMC accumulation at the tumor invasion front and suppresses tumor invasion in cis-Apc/Smad4 mutant mice.\",\n      \"method\": \"CCR1 knockout in tumor mouse model, immunohistochemistry for iMC markers (CD34, MMP9, MMP2), CCL9 expression analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion with defined cellular and functional phenotype; published in high-impact journal\",\n      \"pmids\": [\"17369830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCR1 deficiency (Ccr1-/-) after myocardial infarction leads to diminished neutrophil infiltration, accelerated monocyte/lymphocyte infiltration, decreased apoptosis, increased proliferation, and earlier myofibroblast population, resulting in smaller infarcts and preserved left ventricular function.\",\n      \"method\": \"CCR1 knockout mouse model, LAD ligation MI model, Langendorff isolated heart preparation, immunohistochemistry, echocardiography\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and functional cardiac phenotypes\",\n      \"pmids\": [\"18088392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCR1 mediates macrophage and neutrophil infiltration into the kidney after renal ischemia-reperfusion injury; CCR1-/- mice have 35% fewer neutrophils and 45% fewer macrophages in injured kidneys, and CCR1-/- injured kidneys have reduced CCL3 and CCL5 levels, suggesting a CCR1-dependent positive feedback loop for leukocyte infiltration.\",\n      \"method\": \"CCR1 knockout mice, pharmacological blockade with BX471, flow cytometry, chemokine ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological evidence with defined cellular phenotype\",\n      \"pmids\": [\"19050287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Overexpression of CCR1 in mesenchymal stem cells (MSCs) dramatically increases chemokine-induced migration and protects MSCs from apoptosis in vitro; CCR1-MSCs accumulate in infarcted myocardium at higher levels, reduce infarct size and cardiomyocyte apoptosis, increase capillary density, and restore cardiac function after MI.\",\n      \"method\": \"CCR1 overexpression in MSCs, in vitro migration and apoptosis assays, intramyocardial injection after coronary artery ligation, histology, echocardiography\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with in vitro and in vivo validation, multiple functional readouts\",\n      \"pmids\": [\"20378860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCR1 deletion in mice causes osteopenia due to impaired osteoclast and osteoblast function; Ccr1-/- osteoclasts show abrogated cell fusion and no osteolytic activity with reduced RANK expression, and Ccr1-/- osteoblasts fail to support osteoclastogenesis due to reduced RANKL expression, establishing CCR1 in osteoclast-osteoblast cross-talk via RANK-RANKL axis.\",\n      \"method\": \"CCR1 knockout mice, bone densitometry, osteoclastogenesis assay, mineralized nodule formation, RT-PCR, co-culture experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined cellular mechanism including co-culture epistasis\",\n      \"pmids\": [\"20571024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCR1 on human and mouse colon cancer cells (expressing CCL9/CCL15) recruits CCR1+ CD34+ Gr-1- immature myeloid cells that produce MMP2 and MMP9 to promote liver metastasis; genetic deletion of CCR1 or MMP2/MMP9 in the host dramatically suppresses metastatic outgrowth, and CCR1 antagonist BL5923 blocks iMC accumulation and prolongs survival.\",\n      \"method\": \"CCR1 knockout mouse model, liver dissemination model, immunohistochemistry, CCR1 antagonist treatment, survival analysis\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological evidence in vivo with defined cellular mechanism\",\n      \"pmids\": [\"20616008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Neutrophil Ccr1 amplifies late renal immunopathology in invasive candidiasis by mediating excessive neutrophil recruitment from blood to kidney; Ccr1-/- mice have selectively impaired neutrophil accumulation in the kidney at late timepoints, improved renal function and survival without affecting fungal burden; adoptive transfer of mixed Ccr1+/+ and Ccr1-/- neutrophils confirms cell-autonomous CCR1-dependent trafficking.\",\n      \"method\": \"CCR1 knockout mice, candidiasis model, flow cytometry, adoptive transfer of mixed donor neutrophils, ex vivo chemotaxis assay\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with adoptive transfer (cell-autonomous validation) and functional outcome\",\n      \"pmids\": [\"22916017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCR1 exhibits constitutive activity leading to basal cAMP inhibition, increased F-actin, and basal leukocyte migration; constitutive receptor phosphorylation recruits beta-arrestin-2 and drives G protein-independent receptor internalization. CCR1 simultaneously engages Gαi and beta-arrestin-2 in a multiprotein complex, and pertussis toxin-insensitive chemokine uptake suggests a scavenging function via the CCR1·beta-arrestin-2 complex.\",\n      \"method\": \"cAMP assay, F-actin measurement, migration assay, co-immunoprecipitation of CCR1/Gαi/beta-arrestin-2 complex, receptor internalization assay, pertussis toxin treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple functional assays demonstrating constitutive activity mechanism with complex biochemistry\",\n      \"pmids\": [\"24056371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCR1/CCL5 interaction in taxane-resistant prostate cancer cells (PC3PR) promotes invasion by activating ERK1/2 and Rac1/cdc42 signaling and increasing secretion of MMP-2 and MMP-9; CCR1 siRNA knockdown reduces all these effects and decreases invasion in Matrigel assay.\",\n      \"method\": \"siRNA knockdown, Western blot for p-ERK1/2 and Rac1/cdc42, MMP-2/9 secretion assay, Matrigel invasion assay, MEK1/2 inhibitor\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD with defined signaling pathway and functional invasion readout; single lab\",\n      \"pmids\": [\"23876400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TNFα and IL-1β induce CCL3 expression in nucleus pulposus cells via NF-κB (p65/IKKβ), MAPK, and C/EBPβ signaling; CCL3-conditioned medium promotes macrophage migration that is blocked by a CCR1 antagonist, establishing the CCL3-CCR1 axis in macrophage infiltration in disc degeneration.\",\n      \"method\": \"Transfection/reporter assay, gain- and loss-of-function for p65/C/EBPβ/p50, lentiviral shRNA (shp65, shIKKβ), Transwell migration assay with CCR1 antagonist\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with multiple genetic tools plus functional CCR1-dependent migration; single lab\",\n      \"pmids\": [\"23233369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCL4/Platelet Factor 4 acts as an agonist of CCR1, inducing CCR1 endocytosis and chemotaxis in CCR1-expressing transfectants and primary human monocytes via a pertussis toxin-sensitive, glycosaminoglycan-dependent mechanism; CCR1 antagonist blocks CXCL4-induced monocyte chemotaxis.\",\n      \"method\": \"Transfected cell migration assay, CCR1 endocytosis assay, pertussis toxin treatment, chondroitinase ABC treatment, CCR1 antagonist blockade, primary human monocyte migration\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — receptor transfectant validation plus primary cell confirmation with multiple mechanistic interventions\",\n      \"pmids\": [\"29930254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCR1 activation promotes neuroinflammation after intracerebral hemorrhage via a CCR1/TPR1/ERK1/2 signaling pathway; CCR1 inhibition with Met-RANTES decreases CCR1, TPR1, p-ERK, TNF-α, and IL-1β expression, and these effects are reversed by ERK1/2 activator ceramide C6; TPR1 CRISPR knockdown reverses the neurological effects of rCCL5-induced CCR1 activation.\",\n      \"method\": \"Mouse ICH model, intranasal Met-RANTES, Rac1/ERK1/2 pathway intervention, TPR1 CRISPR, Western blot, immunofluorescence\",\n      \"journal\": \"Neurotherapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo pharmacological and genetic pathway dissection; single lab\",\n      \"pmids\": [\"31898284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Omental macrophages secrete CCL6 (mouse) and CCL23 (human) that promote ovarian cancer migration and colonization via CCR1; CCL6/CCL23 activate ERK1/2 and PI3K signaling in ovarian cancer cells; macrophage depletion and CCR1 inhibition both reduce omental colonization.\",\n      \"method\": \"RNA-sequencing of omental macrophages, macrophage depletion, CCL6/CCL23 knockdown/rescue, CCR1 inhibitor treatment, in vivo omental colonization assay, signaling pathway inhibitors\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological interventions with in vivo colonization readout\",\n      \"pmids\": [\"32963283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structures of the CCR1-Gi complex (2.6-2.9 Å) bound to different N-terminal truncations of CCL15 reveal that conformational change of Tyr291 (Y291^7.43) triggers polar network rearrangement in the orthosteric binding pocket and allosterically regulates beta-arrestin signaling; different CCL15 truncations act as balanced or biased agonists, identifying a structural basis for natural biased signaling at CCR1.\",\n      \"method\": \"Cryo-EM structure determination (3 structures), pharmacological characterization, computational studies, mutagenesis\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure at near-atomic resolution combined with pharmacological and computational validation\",\n      \"pmids\": [\"34949837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The CCL6-CCR1 axis in hematopoietic stem cells (HSCs) promotes eosinophil differentiation and allergic airway inflammation; CCL6 (produced by eosinophils) acts on CCR1 on HSCs to drive eosinophil differentiation, and CCR1 antagonist BX471 markedly decreases eosinophil differentiation and airway inflammation.\",\n      \"method\": \"Ccl6 knockout mice, OVA challenge model, bone marrow analysis, CCR1 antagonist BX471, flow cytometry\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO plus pharmacological blockade with defined cellular mechanism in HSCs\",\n      \"pmids\": [\"33640900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CCR1 and CCR5 on myeloid cells and their precursors mediate cancer-induced MDSC differentiation; tumor-derived factors induce CCL3 and CCL4 in HSPCs that autocrinally engage CCR1 and CCR5 to drive MDSC differentiation (not chemotaxis); silencing CCR1/CCR5 repolarizes PMN-MDSCs into tumoricidal neutrophils and inhibits tumor progression.\",\n      \"method\": \"4PD nanoparticle-mediated in vivo gene silencing of CCR1/CCR5, flow cytometry, transcriptome analysis, cytokine bead arrays, in vitro HSPC differentiation assay with CCR1/CCR5-deficient mice and human cord blood HSPCs\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo silencing with in vitro mechanistic validation across multiple genetic backgrounds and human cells\",\n      \"pmids\": [\"35064009\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCR1 is a constitutively active, Gαi-coupled, seven-transmembrane chemokine receptor that binds multiple CC chemokines (including CCL3/MIP-1α, CCL5/RANTES, CCL7/MCP-2, CCL15, CCL23, and others, the potency of which can be dramatically enhanced by proteolytic N-terminal processing), and whose activation drives leukocyte chemotaxis, osteoclastogenesis, and myeloid cell differentiation via Gαi-dependent signaling; simultaneously, CCR1 forms a complex with β-arrestin-2 for G protein-independent constitutive internalization/scavenging, and its structural basis for biased versus balanced signaling has been resolved by cryo-EM, revealing that conformational change of Tyr291 allosterically gates β-arrestin pathway engagement.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCR1 is a Gαi-coupled seven-transmembrane chemokine receptor that binds multiple CC chemokines — including CCL3/MIP-1α, CCL5/RANTES, CCL7/MCP-3, CCL15, and CCL23 — to drive leukocyte chemotaxis, osteoclastogenesis, and myeloid cell differentiation in diverse inflammatory, fibrotic, and neoplastic contexts [PMID:9329966, PMID:9115216, PMID:15537451, PMID:35064009]. Ligand binding triggers Gαi-dependent signaling including calcium mobilization, cAMP inhibition, and ERK1/2 activation, while CCR1 simultaneously exhibits constitutive activity that recruits β-arrestin-2 for G protein-independent internalization and chemokine scavenging [PMID:24056371, PMID:10734056]. Proteolytic N-terminal processing of ligands such as CCL15 and CCL23 by inflammatory proteases can enhance CCR1 potency up to 1000-fold, and cryo-EM structures of the CCR1–Gαi complex revealed that conformational switching of Tyr291 allosterically gates β-arrestin pathway engagement, providing a structural basis for biased agonism [PMID:15905581, PMID:34949837]. In vivo, CCR1 on neutrophils, macrophages, and CD34⁺ immature myeloid cells mediates their recruitment to sites of inflammation, fibrosis, and tumor invasion, and CCR1 signaling on hematopoietic stem and progenitor cells drives eosinophil and MDSC differentiation through autocrine/paracrine chemokine loops [PMID:14747380, PMID:17369830, PMID:33640900, PMID:35064009].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing CCR1 as a functional chemokine receptor for MIP-1α and RANTES whose deletion protects against systemic inflammatory injury resolved the question of whether CCR1 has a non-redundant role in leukocyte-driven inflammation in vivo.\",\n      \"evidence\": \"CCR1 knockout mice with pancreatitis-associated lung injury; radioligand binding and chemotaxis in CCR1-transfected cells\",\n      \"pmids\": [\"9329966\", \"9115216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathways not yet defined\", \"Relative contribution of individual ligands to disease phenotype unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that the RANTES N-terminus is essential for CCR1 activation and that small-molecule antagonists can block CCR1 signaling established the pharmacological tractability of CCR1 and the structural determinants of ligand recognition.\",\n      \"evidence\": \"Truncated RANTES variants in calcium mobilization and chemotaxis assays; 4-hydroxypiperidine antagonists in binding, acidification, calcium, and migration assays\",\n      \"pmids\": [\"9565366\", \"9624164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No receptor structure available\", \"Mechanism of antagonist binding not resolved at atomic level\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of phosphorylation-dependent desensitization, cross-desensitization by CXCR1/CXCR2, and functional CCR1 expression on platelets and astrocytes broadened the receptor's signaling regulation and cellular context beyond classical leukocyte chemotaxis.\",\n      \"evidence\": \"Alanine-scanning mutagenesis with GTPase/Ca²⁺ assays in RBL-2H3 cells; immunoprecipitation and aggregation assays on human platelets; TGFβ1-induced CCR1 upregulation in astrocytes\",\n      \"pmids\": [\"10734056\", \"11110672\", \"10696139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinases responsible for CCR1 phosphorylation not identified\", \"In vivo relevance of platelet CCR1 not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Pharmacological CCR1 blockade with BX471 reducing renal fibrosis after ureteral obstruction, later validated by CCR1 knockout and adoptive transfer, established that CCR1 on leukocytes is the primary driver of inflammatory cell recruitment leading to organ fibrosis.\",\n      \"evidence\": \"BX471 antagonist in mouse UUO model; CCR1/CCR5 knockout comparison with adoptive transfer of CCR1-deficient leukocytes\",\n      \"pmids\": [\"11805137\", \"14747380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCR1 on resident renal cells contributes was not fully excluded\", \"Fibrotic signaling downstream of CCR1 on recruited cells not dissected\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery that proteolytic N-terminal truncation of CCL15 and CCL23 enhances CCR1 potency up to 1000-fold, and that NFAT2 transcriptionally activates CCR1 during RANKL-induced osteoclastogenesis, defined two key regulatory layers — extracellular ligand processing and transcriptional control — governing CCR1-mediated responses.\",\n      \"evidence\": \"In vitro protease cleavage with mass spectrometry and CCR1 signaling/chemotaxis assays; CCR1 promoter-luciferase with CsA inhibition and siRNA in osteoclast precursors\",\n      \"pmids\": [\"15905581\", \"16355273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of truncated ligand forms not established in genetic models\", \"Full promoter regulatory elements for CCR1 not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic epistasis using CCR1−/−, CCR5−/−, and MIP-1α−/− mice demonstrated that CCR1 (not CCR5) mediates MIP-1α-driven neutrophil migration via sequential TNF-α and LTB4 release, resolving receptor-specific signaling hierarchy in immune inflammation.\",\n      \"evidence\": \"Multiple knockout strains in peritoneal inflammation model with TNF-α/LTB4 measurement\",\n      \"pmids\": [\"15831559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this TNF-α→LTB4 cascade applies in all tissues not tested\", \"Direct biochemical link between CCR1 and TNF-α secretion machinery unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showing that CCR1-expressing CD34⁺ immature myeloid cells are recruited to the tumor invasion front via CCL9 and that CCR1 deletion suppresses tumor invasion established CCR1 as a mediator of pro-tumorigenic myeloid cell recruitment.\",\n      \"evidence\": \"CCR1 knockout in cis-Apc/Smad4 mutant intestinal tumor mouse model with immunohistochemistry for CD34/MMP markers\",\n      \"pmids\": [\"17369830\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human relevance of CCL9/CCR1 axis in tumor invasion not directly tested\", \"Whether CCR1 on tumor cells themselves contributes was not dissected\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"CCR1 knockout in bone revealed that CCR1 regulates not only osteoclast fusion and motility but also osteoblast RANKL expression, establishing a dual role in osteoclast-osteoblast cross-talk via the RANK-RANKL axis.\",\n      \"evidence\": \"CCR1 knockout mice with bone densitometry, osteoclastogenesis, and osteoblast co-culture assays\",\n      \"pmids\": [\"20571024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling linking CCR1 to RANKL transcription in osteoblasts unknown\", \"Whether CCR1 ligand identity differs in bone microenvironment not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that CCR1 is constitutively active — with basal Gαi coupling, β-arrestin-2 recruitment, and receptor internalization — and that it simultaneously engages Gαi and β-arrestin-2 in a multiprotein complex revealed a scavenging function independent of classical G protein signaling.\",\n      \"evidence\": \"cAMP, F-actin, migration, and co-immunoprecipitation assays with pertussis toxin in CCR1-expressing cells\",\n      \"pmids\": [\"24056371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for constitutive activity not yet determined\", \"Physiological relevance of constitutive scavenging in vivo not demonstrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cryo-EM structures of CCR1–Gαi with different CCL15 truncations at 2.6–2.9 Å resolved the structural basis for biased agonism: conformational change of Tyr291 rearranges a polar network that allosterically gates β-arrestin engagement, directly answering how ligand processing generates balanced versus biased signaling.\",\n      \"evidence\": \"Three cryo-EM structures with mutagenesis and pharmacological characterization\",\n      \"pmids\": [\"34949837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of CCR1–β-arrestin complex available\", \"How Tyr291 conformational switch mechanistically propagates to intracellular surface not fully modeled\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Establishing that tumor-derived factors induce autocrine CCL3/CCL4–CCR1/CCR5 signaling in HSPCs to drive MDSC differentiation (rather than chemotaxis) revealed a non-migratory, differentiation-instructive function of CCR1 in cancer immune evasion.\",\n      \"evidence\": \"In vivo nanoparticle-mediated gene silencing, HSPC differentiation assays in CCR1/CCR5-deficient mice and human cord blood cells\",\n      \"pmids\": [\"35064009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CCR1 versus CCR5 in MDSC differentiation not fully deconvolved\", \"Downstream transcriptional programs linking CCR1 to myeloid fate specification not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the CCR1–β-arrestin-2 complex, the in vivo relevance of constitutive scavenging activity, and how CCR1 signaling mechanistically switches between chemotactic and differentiation-instructive outputs in hematopoietic progenitors.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No CCR1–β-arrestin complex structure\", \"Kinases mediating CCR1 constitutive phosphorylation unknown\", \"Transcriptional programs downstream of CCR1 in HSPCs not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2, 3, 32, 38]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 10, 17, 32, 35]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 10, 32, 33, 36, 38]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 4, 5, 9, 15, 20, 27, 31, 39, 40]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [29, 39, 40]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCL3\",\n      \"CCL5\",\n      \"CCL15\",\n      \"CCL23\",\n      \"ARRB2\",\n      \"GNAI1\",\n      \"LZIP\",\n      \"CXCL4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}